Please login to the form below

Not currently logged in
Email:
Password:

Achillion

This page shows the latest Achillion news and features for those working in and with pharma, biotech and healthcare.

J&J buys firm seeking hepatitis B cure

J&J buys firm seeking hepatitis B cure

J&J is also continuing to research new HCV therapies, and earlier this year paid up to $1.1bn for the rights to Achillion Pharmaceuticals' pipeline of drugs, headed by

Latest news

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Managing value: Why early asset development and commercialisation are important Managing value: Why early asset development and commercialisation are important

    For example, Alnylam Pharmaceuticals, with its lead product in phase III, has a market capitalisation of $7.4bn, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation of

  • Pharma deals in May 2015 Pharma deals in May 2015

    Clearly a very successful and creative partnership! Choosing to opt for partnership over an acquisition, J&J closed a multiple licence with Achillion to build on its hepatitis C portfolio. ... 1, 300. Achillion/ J&J. Licence. Joint development and

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics